Loading…
Loading…
BPMC (Blueprint Medicines Corporation) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
BPMC does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for BPMC and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BPMC and 80,000+ other tickers.
See exactly how BPMC's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BPMC and 80,000+ other tickers.
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally…
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) and its transaction with Sanofi. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Blueprint insiders received substantial benefits as part of change of control arrangements and certain insiders may have had conflicts of interests. We are investigating whe.
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Blueprint Medicines Corporation (NASDAQ: BPMC ) related to its sale to Sanofi, S.A. Under the terms of the proposed transaction, Sanofi will pay $129.00 per share in cash at closing, and Blueprint shareholders also will receive one non-tradeable contingent value right (“CVR”) entitling the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. Is it a fair deal?
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Blueprint Medicines Corporation (NasdaqGS: BPMC) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Blueprint will receive $129.00 per share in cash at closing, and also will receive one non-tradeable contingent value right (CVR) entitling the holder to receive t.
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Blueprint Medicines Corporation (NASDAQ: BPMC ) related to it sale to Sanofi. Under the terms of the proposed transaction, Sanofi will pay $129.00 per share in cash at closing, and Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) entitling the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. Is it a fair deal?
-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis -- CAMBRIDGE, Mass. , June 12, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic mastocytosis (SM).